Thank you. And once again, welcome to ADDvise Group 2024 Second Quarter Earnings Call. The second quarter this year showed mixed financial performance. Our net sales came in at 412 million SEK. Which reflects a year-on-year growth of 20%. However, we faced challenging pharma and clinical trial comparables following last year's exceptional performance in two of our businesses.
This resulted in a negative organic growth isolated to the quarter of -21%. Just to provide some context on the underlying businesses, Normally, I don't adjust for items, but just to signify the impact of these two businesses and how the rest of the 19 businesses performed. After excluding the two exceptional businesses, Forma Pharma and European clinical trials. Without these two, our isolated organic growth for the quarter would have been 13%.
Of course, the reported number is what it is, but this provides more clarity on the negative organic growth. It's worth mentioning that the two businesses that outperformed last year are still aligning with or exceeding the performance they had when we acquired them, even though they are not at last year's levels during 2024. EBITDA came in at 102 million, resulting in an unadjusted EBITDA margin of 25%. We had our best quarter ever in terms of order intake. Overall, the order intake came in at 67% and 13% respectively;
This was measured by organic levels. Specifically, within our laboratory segment, you can find the drivers behind these large numbers. As you recall from last year, we did not achieve the desired cash conversion from operating earnings down to net profit. A few reasons were the tax inefficiencies in our ADDvise group last CY. Also, significant depreciation due to a large volume of clinical trial rental revenues affected our calculations.
So, we have put a lot of effort into minimizing the disparity between operating profit and the final net profit, which we have succeeded in doing. Looking at the net profitability for the quarter, we are sitting at around 30 million SEK compared to 3 million last year. Earnings per share were 0.15 SEK. This is an improvement compared to last year.
Assessing the cash flow for the quarter leaves me unsatisfied, due to some net working capital buildup influenced by the product mix, something that I will address later in the presentation. Our liquidity is strong, with over 400 million in cash and cash equivalents and an undrawn credit facility on top of that. In our Nordic businesses, we witnessed strong momentum this quarter. As mentioned earlier, the demand for climate and clean room solutions outperformed this quarter.
This demand, geographically driven by our Middle Eastern customers, is motivated by their desire to reduce oil dependency and invest in more sustainable businesses in that region. This sustainability focus bolsters research and pharma development, which in turn drives demand in our businesses operating in climate and clean room solutions. In May, we also secured our largest single order to date, $11.3 million to an Omani customer building a research facility in Oman. South America is also a strong market for us currently. We see high growth rates in that region and our businesses operating in Brazil. I have very good momentum. Unfortunately, that business is not part of the organic growth calculation yet, because we haven't owned that business for 12 months. So that will come into the numbers. It will be included as of the fourth quarter this year.
As mentioned before, the clinical trials saw some challenging comparables after the exceptional year in 2023. But that is only in the European part of the clinical trials business. Our recently acquired North American business within clinical trials is performing according to or slightly above the levels we were promised before the acquisition. The same thing applies here; they're not part of the organic growth calculation. It will come into the numbers later this year.
The demand for capital goods in the US remains a bit soft in the quarter. We saw some improvement late in the second quarter. The signals we get from our customers suggest that interest rates still hurt investment in capital equipment. When the Fed starts to cut interest rates, we believe the demand in that market will bounce back. In terms of geography, 44% of our sales in the quarter came from North America.
Our main US market, the second largest for us, is Europe, excluding Sweden. And the third one is South America. So we have a well-diversified geographical exposure in the ADDvise group. As we stand today, looking at the four or five product categories that we measure, the largest one year-to-date in the second quarter is laboratory equipment, followed by medical consumables and medical equipment. As you can see on this pie chart, pharma is now down at 7% of ADDvise group's sales.
Year to date in the second quarter. If you compare that to last year, we were around 20-25% of ADDvise group sales, and as I've said several times before, the pharma revenues that we have come with much higher margins. But at the same time, the flip side of that is that the revenues are more volatile than the rest of our ADDvise group. But when we are down at 7 or 8% where we are right now, I see the volatility on the upside rather than the downside. So for us, the 7% that we see today are very robust compared to where we were last year.
On this slide, you see the growth trajectory over the last four years. As you can see, we have, for the first time, surpassed 1.5 billion SEK in sales. And if you look at the quarter isolated, we came in at 412 million SEK. Organic growth dropped 21% due to the reasons I just mentioned. At the ADDvise group level, we split our revenues between our own proprietary products, which we develop and manufacture, and products that we distribute, which we do not own; and in the second quarter, year-to-date, our own products accounted for close to 60% of our sales. And that is typically the balance that we would like to have going forward. Around 60% owned products and 30%-35% distribution and the rest as service revenues. Order intake was the strongest quarter ever at 134 million. 67% total growth in order intake. Organically, 13% up. The main driver, as mentioned, several companies contributed to the growth.
But the main driver that stands out was the laboratory, clean room, and climate room solutions that boosted the order intake in the quarter. So going into the second half of this year, we have a solid order backlog to convert into sales in the upcoming quarters, dividing our advice group into healthcare and lab segments, focusing on healthcare. Our sales came in at 256 million in the quarter. Organic growth dropped 12%. If you exclude the pharma revenues from this segment, the organic growth would have been 9% in the quarter.
This discrepancy essentially skews the numbers between the two businesses. One is in the healthcare segment and the other in the laboratory segment. Total sales grew by 28% in the quarter. We closed the quarter with a 19% EBIT Wild margin. Looking at the laboratory segment, slightly smaller as part of the advice group, with sales of 157 million. Organic growth was at -33%. Following the same calculation here, stripping out European clinical trial business,
the organic growth would have been 24% in the quarter, isolated margin-wise with an operating margin of 25% in the quarter. In isolated geography, you can see on the pie charts that we have slightly different geographical exposures in the two segments. North America is the key market for the healthcare segment and will continue to be that for a long time. However, South America is a very fast-growing market compared to the other markets,
which are slightly more mature. South America is a very fast-growing market. In the laboratory segment, the rest of the world is now the largest market for us. This is driven by, as I mentioned in the presentation earlier, Middle Eastern customers investing heavily in sustainable businesses, most of all in research and pharma businesses. We supply them with clean room facilities, climate rooms, and equipment used in these facilities. Europe, excluding Sweden, is the second-largest market, and 25%, or a quarter of the sales, comes from Sweden. And that is, of course, where it all started for the ADDvise group, many years ago in Sweden. Financial performance. We are now on a rolling 12-month basis at around 420 million in EBITDA. On a margin level, we achieved a rolling 12-month margin of 27% and isolated in the quarter at 25%. The drop in margin is mainly affected by the product mix. As mentioned before, Pharma, which is a much smaller portion of our ADDvise group today compared to last year, comes with a much higher margin compared to the project business for clean rooms and climate rooms, which carries a lower margin. And that, of course, affects the group margin. Margin. Weaker operating earnings but improved net profitability. Our EBITDA came down from 122 million to 102 million in the quarter. And if you look at earnings before interest and tax, you saw a drop of 8% from 87 to 80. On the other hand, net profitability increased significantly from 3 million to 30 million. Um, and the drivers for the increased net profitability are several. It's a more tax-efficient structure, improving the, uh, or lowering the tax rate. A lower amount of depreciation in the quarter was based on a reduced volume of clinical trial rental business.